Castle Biosciences Beats Q3 2026 Estimates as Revenue Rises 23% to $101.9M

Castle Biosciences (CSTL) beat estimates for the third quarter of 2026 on both revenue and EPS. Revenue was $101.9 million, up 23% from a year earlier, above the $92.8 million estimate, and EPS was -$0.13, down 550% from a year earlier, above the -$0.35 estimate.

Shares rose 3.2% in after-hours trading as of 4:18 p.m. ET, to $35.29 from a $34.20 close.

Q3 2026 scorecard

By our calculation, revenue was $9.2 million above the estimate and EPS was $0.22 above it. The QoQ column compares with the previous quarter's revenue of $103.5 million and EPS of -$0.07. The YoY column compares with $83.0 million and -$0.02 in the same quarter a year earlier.

GAAP results

• Net loss. The company reported a net loss of $4.1 million on a GAAP basis, compared with a net loss of $501 thousand a year earlier.

Track record

• EPS record. EPS beat the estimate in 6 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 8 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $83.0 million, $87.0 million, $84.2 million, $103.5 million and $101.9 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$0.35 and revenue of $94.6 million next quarter, based on 5 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 23% increase to $101.9 million.
• Estimate record. Whether Castle Biosciences extends a record of beating EPS estimates in 6 of its last 8 reports.
• Related coverage. See our reports on Vera Therapeutics, Helios, Ameren and Chesapeake Utilities.

Sources: Results are from Castle Biosciences's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Castle Biosciences's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.